Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Public ClinicalTrials.gov record NCT01199263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC # 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase II trial studies the side effects and how well giving paclitaxel with or without viral therapy works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Viral therapy may be able to kill tumor cells without damaging normal cells. Giving paclitaxel together with viral therapy may kill more tumor cells.
Study identification
- NCT ID
- NCT01199263
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Interventions
- Laboratory Biomarker Analysis Other
- Paclitaxel Drug
- Pelareorep Biological
Other · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2010 (Actual)
- Primary completion
- Jun 1, 2015 (Actual)
- Completion
- Jul 17, 2020 (Actual)
- Last update posted
- Sep 16, 2020
2010 – 2020
United States locations
- U.S. sites
- 36
- U.S. states
- 17
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank | California | 91505 | — |
| Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View | California | 94040 | — |
| Smilow Cancer Hospital Care Center at Saint Francis | Hartford | Connecticut | 06105 | — |
| Northeast Georgia Medical Center-Gainesville | Gainesville | Georgia | 30501 | — |
| Saint Alphonsus Cancer Care Center-Boise | Boise | Idaho | 83706 | — |
| Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Michigan Cancer Research Consortium NCORP | Ann Arbor | Michigan | 48106 | — |
| Saint Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| Beaumont Hospital - Dearborn | Dearborn | Michigan | 48124 | — |
| Ascension Saint John Hospital | Detroit | Michigan | 48236 | — |
| Hurley Medical Center | Flint | Michigan | 48503 | — |
| Genesys Regional Medical Center | Grand Blanc | Michigan | 48439 | — |
| Allegiance Health | Jackson | Michigan | 49201 | — |
| Sparrow Hospital | Lansing | Michigan | 48912 | — |
| Saint Mary Mercy Hospital | Livonia | Michigan | 48154 | — |
| Saint Joseph Mercy Oakland | Pontiac | Michigan | 48341 | — |
| Lake Huron Medical Center | Port Huron | Michigan | 48060 | — |
| Ascension Saint Mary's Hospital | Saginaw | Michigan | 48601 | — |
| Saint John Macomb-Oakland Hospital | Warren | Michigan | 48093 | — |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Women's Cancer Center of Nevada | Las Vegas | Nevada | 89169 | — |
| University of New Mexico Cancer Center | Albuquerque | New Mexico | 87102 | — |
| Atrium Health Cabarrus/LCI-Concord | Concord | North Carolina | 28025 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland | Ohio | 44111 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Hillcrest Hospital Cancer Center | Mayfield Heights | Ohio | 44124 | — |
| UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor | Ohio | 44060 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | 75390 | — |
| Carilion Clinic Gynecological Oncology | Roanoke | Virginia | 24016 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01199263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01199263 live on ClinicalTrials.gov.